Drug Formulary Review Archives – October 1, 2003
October 1, 2003
View Issues
-
Federal incentive has increased number of pediatric drug studies
Federal incentive for pharmaceutical companies to study drugs in children has led to improved labeling for several medications. More needs to be done, though, and pharmacists can play a key role in encouraging the process, says one pediatrician. -
Study: Antibiotic use among U.S. children reduced
The overuse of antibiotics in children may be subsiding, according to a study published in the September issue of Pediatrics. -
Sertraline effective in pediatric depression
Two recent warnings have led to concerns about the risks of prescribing antidepressants to children. -
Oxcarbazepine (Trileptal) approved as monotherapy in children with epilepsy
The U.S. Food and Drug Administration has approved the first antiepileptic drug for monotherapy in children since 1978. -
News Briefs
Study: Pharmacists intervention can help keep men healthy; Interstitial cystitis study finds limited benefit in two oral drugs; FDA to inform women about menopausal hormone therapy; Wyeth issues warning about venlafaxine use in children -
New FDA Approvals
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA): -
Gemifloxacin (Factive) Drug Evaluation
Gemifloxacin is effective as standard treatment for the treatment of ABECB and CAP; however, in limited trials it does not seem to be more efficacious or safe than other standard drug therapy for these indications. -
Free audio conference looks at contraceptive
Extended hormonal contraception is drawing dramatic attention due to the desire of many women to reduce or eliminate the number of withdrawal bleeds associated with current birth control methods. -
Audio conference clarifies final EMTALA regulations
The final version of the recently proposed changes to the Emergency Medical Treatment and Labor Act (EMTALA) takes effect Nov. 10.